Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Atezolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention. Browse Atezolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 6:00 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
512
Shown on this page
12
Current sort
Recently updated
Therapy scope
Atezolizumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Atezolizumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 469–480 of 512 matching trials for Atezolizumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02174172
View directory record Official record
Conditions
Solid Cancers
Interventions
Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Completed Phase 2 Interventional Results available

A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02848651
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
Fresno, California • Hollywood, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Completed Phase 1 Interventional

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT02013219
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib, Atezolizumab, Erlotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
Orange, California • New Haven, Connecticut • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC

NCT03371992
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Nivolumab, 3D-EX, Evaluation of Response by RECIST
Drug · Diagnostic Test · Other
Lead sponsor
Nilogen Oncosystems
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Completed Phase 1 Interventional

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

NCT02892318
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Atezolizumab, Guadecitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Duarte, California • New Haven, Connecticut • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Terminated Phase 1 Interventional

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

NCT02784483
View directory record Official record
Conditions
Asymptomatic Myeloma
Interventions
Atezolizumab (1200mg via IV infusion)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

NCT02541604
View directory record Official record
Conditions
Solid Tumor
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Little Rock, Arkansas • Palo Alto, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Completed Phase 1 Interventional

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

NCT02650713
View directory record Official record
Conditions
Solid Tumors
Interventions
Atezolizumab, RO6958688
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Santa Monica, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Terminated Phase 1 Interventional Results available

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

NCT03267940
View directory record Official record
Conditions
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma
Interventions
PEGPH20, CIS, GEM, Atezolizumab
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915
View directory record Official record
Conditions
HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
Interventions
Atezolizumab, Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Completed Phase 1 Interventional

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

NCT02220842
View directory record Official record
Conditions
Lymphoma
Interventions
Atezolizumab, Obinutuzumab, Tazemetostat
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Duarte, California • Fort Wayne, Indiana • Hackensack, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Nov 1, 2026, 6:00 AM EST
Terminated Phase 2 Interventional Results available

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

NCT03007719
View directory record Official record
Conditions
Bladder Cancer
Interventions
Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Lawrence Fong
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Nov 1, 2026, 6:00 AM EST

About this Atezolizumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Atezolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Atezolizumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Atezolizumab.